1 Name
(1) This instrument is the National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 1).
(2) This instrument may also be cited as PB 2 of 2024.
2 Commencement
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
Commencement information |
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. The whole of this instrument | 1 February 2024 | 1 February 2024 |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
3 Authority
This instrument is made under subsection 84AAA(2) of the National Health Act 1953.
4 Schedules
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1—Amendments
National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)
[1] Schedule 1, entry for Eprosartan
omit:
| Tablet 400 mg (as mesilate) | 20 | 56 | 5 | |
[2] Schedule 1, omit entry for Ertugliflozin
[3] Schedule 1, omit entry for Ertugliflozin with sitagliptin
